Latest news with #Enbrel
Yahoo
15-05-2025
- Business
- Yahoo
Enbrel (Etanercept) Market Research Report 2025: Epidemiology, Pipeline Analysis, Insights & Forecasts 2019-2024, 2024-2029F, 2034F
Dublin, May 15, 2025 (GLOBE NEWSWIRE) -- The "Enbrel (Etanercept) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to Enbrel (Etanercept) market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market. Enbrel (etanercept) is a biologic medication that treats various autoimmune conditions by inhibiting the activity of tumor necrosis factor (TNF), a protein involved in inflammation. It is a synthetic version of a naturally occurring protein in the body, designed to bind to TNF and block its interaction with its receptors, reducing inflammation. Enbrel is usually administered through subcutaneous injection, either by a healthcare professional or by patients themselves at home. Major players operating in the enbrel (etanercept) market are Amgen Inc; Pfizer Inc. North America was the largest region in the enbrel (etanercept) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in enbrel (etanercept) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the enbrel (etanercept) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, primary types of enbrel (etanercept) include brand drugs and biosimilars. It is used to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis by blocking TNF. Enbrel is available in both liquid solution and powder for injection growth observed during the historic period can be attributed to the approval of multiple indications, strong adoption by physicians, the introduction of patient-friendly injection devices, a growing healthcare focus on cost-effective treatments for chronic diseases, extensive clinical trials, and positive growth during the forecast period can be driven by the aging global population, the increasing prevalence of autoimmune diseases, rising preference for biologics, the introduction of biosimilars, and increased government funding and insurance coverage. Key trends during this period include its use in pediatric populations, a rise in home-based treatments, integration of digital health, combination therapy approaches, and advancements in genomics and biomarker surging prevalence of autoimmune conditions is expected to significantly propel the growth of the enbrel (etanercept) market. Autoimmune conditions, where the immune system mistakenly attacks the body's healthy tissues, are increasing due to factors such as genetic susceptibility, environmental triggers, and improved diagnosis and awareness. Enbrel, which inhibits tumor necrosis factor-alpha (TNF-a), is highly effective in treating autoimmune disorders such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. By blocking TNF-a, Enbrel helps reduce inflammation, alleviate symptoms, and slow disease progression. For instance, in June 2024, the Australian Institute of Health and Welfare reported that 514,000 Australians were living with rheumatoid arthritis in 2022. The increasing prevalence of such conditions will continue to drive demand for enbrel.A key trend in the enbrel (etanercept) market is the development of innovative TNF inhibitors to manage autoimmune diseases. TNF inhibitors block the TNF protein, which is responsible for inflammation and immune responses, thereby helping to reduce symptoms like joint swelling and pain. In October 2023, Amgen Inc. received U.S. Food and Drug Administration (FDA) approval for Enbrel to manage juvenile psoriatic arthritis (JPsA) in children aged two and older. This approval marks a significant advancement in the use of Enbrel for younger Topics Covered: 1. Executive Summary2. Enbrel (Etanercept) Market Characteristics3. Enbrel (Etanercept) Market Biologic Drug Characteristics3.1. Molecule Type3.2. Route of Administration (ROA)3.3. Mechanism of Action (MOA)3.4. Safety and Efficacy4. Enbrel (Etanercept) Market Trends and Strategies5. Enbrel (Etanercept) Market - Macro Economic Scenario Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market6. Global Enbrel (Etanercept) Growth Analysis and Strategic Analysis Framework6.1. Global Enbrel (Etanercept) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)6.2. Analysis of End Use Industries6.3. Global Enbrel (Etanercept) Market Growth Rate Analysis6.4. Global Enbrel (Etanercept) Historic Market Size and Growth, 2019-2024, Value ($ Billion)6.5. Global Enbrel (Etanercept) Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Billion)6.6. Global Enbrel (Etanercept) Total Addressable Market (TAM)7. Global Enbrel (Etanercept) Market Pricing Analysis & Forecasts8. Enbrel (Etanercept) Market Segmentation8.1. Global Enbrel (Etanercept) Market, Segmentation by Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Brands Drugs Biosimilar Drugs 8.2. Global Enbrel (Etanercept) Market, Segmentation by Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Liquid Solution Powder For Injections 8.3. Global Enbrel (Etanercept) Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Rheumatoid Arthritis Psoriatic Arthritis Ankylosing Spondylitis Juvenile Idiopathic Arthritis 9. Global Enbrel (Etanercept) Market Epidemiology of Clinical Indications9.1. Drug Side Effects9.2. Incidence and Prevalence of Clinical Indications10. Enbrel (Etanercept) Market Regional and Country Analysis10.1. Global Enbrel (Etanercept) Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion10.2. Global Enbrel (Etanercept) Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
09-05-2025
- Business
- Yahoo
Is Amgen Inc. (AMGN) the Best Dow Stock?
We recently published a list of . In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other Dow stocks. The Dow Jones Industrial Average is a benchmark index of the top 30 companies in the US. It represents the strength of the US economy and carries great historical significance as well. It also acts as a reference point for analysts and investors. However, not all stocks within this elite group of companies perform equally. While some thrive on innovation and economic boom, others struggle due to various setbacks and economic trends. We decided to break down the index and find out the best and worst stocks, looking at what was making them perform unexpectedly this year. In order to come up with our ranking of the best and worst Dow stocks, we first assigned a rank to each stock based on the number of hedge funds holding the stock. We then looked at the short interest in each stock and assigned the top rank to the company with the least short interest. We then combined the two ranks to see which stock was the best on average. The list is in ascending order, with the best stock taking the number one spot. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). A pharmacist filling a prescription for a complex drug developed by the Interest as of Apr 30, 2025: 2.71% Amgen Inc. (NASDAQ:AMGN) operates as a manufacturer, developer, discoverer, and deliverer of human therapeutics. Its key product candidates are Enbrel, XGEVA, Otezla, KYPROLIS, Prolia, Repatha, Nplate, Aranesp, EVENITY, Vectibix, BLINCYTO, and others. It serves dialysis centers, pharmacies, hospitals, and physicians. The firm recently announced plans to invest an additional $900 million to expand its Ohio biotech manufacturing facility. According to Bloomberg's report, this expansion will create hundreds of new jobs. This move will help the company to improve its global biomanufacturing network. Chairman and CEO at Amgen, Robert A. Bradway commented: 'Amgen has been a leading U.S.-based manufacturer of biologic medicines since 1988. Today's investment reinforces our ongoing commitment to expanding U.S. manufacturing and ensuring patients around the world have access to our innovative medicines. Ohio offers a supportive business climate, skilled workforce, and strategic location, making it an ideal choice for this next phase of our investment.' At the start of this month, the firm received an expanded FDA label approval for Uplizna. The FDA has approved it as the first treatment for Immunoglobulin G4-related disease (IgG4-RD) for adults. This approval is based on the late-stage clinical trial results indicating that Uplizna reduced the risk of disease reactivation by 87%. Overall, AMGN ranks 28th on our list of best and worst Dow stocks. While we acknowledge the potential of AMGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than AMGN but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
01-05-2025
- Business
- Yahoo
Amgen quarterly profit tops Wall Street view, sales up 11%
By Deena Beasley (Reuters) -Amgen on Thursday said its first-quarter profit rose 24%, handily exceeding Wall Street expectations, as product sales increased 11% and profit margins widened. The biotechnology company reported adjusted earnings per share of $4.90 for the quarter, sailing past the average analyst estimate of $4.30, as compiled by LSEG. Overall revenue rose 9% to $8.1 billion, which was in line with Wall Street estimates. "Ongoing new product launches and successful Phase 3 trial results for several products make us feel confident in our long-term growth prospects," Amgen CEO Robert Bradway said in a statement. The company is slated to present at a medical meeting next month full results from a mid-stage trial of its experimental weight-loss drug MariTide, viewed by many investors as a potential blockbuster. Amgen is conducting late-stage trials of the drug in patients with and without diabetes, and said results from a Phase 2 diabetes trial will be announced in the second half of this year. The company also said the U.S. Food and Drug Administration has lifted its clinical hold on an early-stage trial of a different experimental weight-loss drug known as AMG 513. For the full year, Amgen said it still expects adjusted earnings per share of $20.00 to $21.20 on revenue of $34.3 billion to $35.7 billion. Analysts, on average, have estimated earnings of $20.63 per share on revenue of $35.1 billion. Amgen said its 2025 outlook includes the impact of implemented tariffs, but does not account for any future levies, including potential sector-specific tariffs. U.S. President Donald Trump's administration has opened a national security investigation into pharmaceuticals in a bid to demonstrate why the U.S. needs tariffs to boost domestic manufacturing. Amgen's first-quarter sales of bone drug Prolia rose 10% to $1.1 billion, but the company said it expects lower sales of the medication later in the year as biosimilar competitors are launched. Sales of cholesterol-lowering medication Repatha rose 27% to $656 million, while sales of much older arthritis drug Enbrel fell 10% to $567 million. In the rare disease space, sales of thyroid eye disease drug Tepezza fell 10% to $381 million, and sales of gout treatment Krystexxa were flat at $236 million. Both drugs were acquired with Amgen's purchase of Horizon Therapeutics. Net operating income for the quarter rose 20% to $1.2 billion. (Reporting By Deena BeasleyEditing by Bill Berkrot) Sign in to access your portfolio
Yahoo
29-04-2025
- Business
- Yahoo
If You'd Invested $10,000 in Pfizer Stock 10 Years Ago, Here's How Much You'd Have Today
Few would dispute that Pfizer (NYSE: PFE) is an icon within the pharmaceutical world. And, giving credit where it's due, the drugmaker largely led the charge against the COVID-19 pandemic with both a vaccine and treatment. Anyone keeping tabs on this ticker of late, however, likely knows it's also been a disappointment since its contagion-driven peak. Indeed, thanks to more than a 60% pullback from its late-2021 high, investors that committed $10,000 to a position in Pfizer 10 years ago -- when its anti-cholesterol drug Lipitor, arthritis-fighting Enbrel, pneumonia vaccine Prevnar, and nerve pain and epilepsy treatment Lyrica were still firing on all cylinders -- would now be holding just a little over $7,000 worth of this pharmaceutical stock. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Things get measurably better when factoring in any reinvested dividends paid in the meantime, though, as the chart below illustrates. The position becomes a net winner, in fact, albeit a small one. All told, reinvesting all the dividends in more shares of this stock as they were paid would leave you with just a tad over $10,600 for the 10-year time frame, although this still trails the broad market's total returns for this stretch by a country mile. Obviously, most of the setback here was suffered just since early 2022, when this position would have been worth a little more than $18,000. The market has clearly reacted to slowing sales of its COVID-19 treatment Paxlovid and its COVID-19 vaccine Comirnaty, which hasn't been offset by equally sized growth from other drugs in its portfolio. Just don't jump to conclusions about a stock's probable future based on its recent (and not-so-recent) past, even when that historical weakness is as dramatic and prolonged as Pfizer's has been. In this particular instance, the bears have arguably overshot their target, ignoring Pfizer's newer growth prospects, especially on the oncology front. The stock's forward-looking dividend yield of 7.5% makes a new position in this company even more compelling if you are confident of the company's future. Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $594,046!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $680,390!* Now, it's worth noting Stock Advisor's total average return is 872% — a market-crushing outperformance compared to 160% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of April 28, 2025 James Brumley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy. If You'd Invested $10,000 in Pfizer Stock 10 Years Ago, Here's How Much You'd Have Today was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
28-04-2025
- Business
- Yahoo
Sandoz CEO slams EU-wide drug price proposal, warns US tariffs will hurt patient access
By Maggie Fick LONDON (Reuters) -The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide list price for new medicines is "deeply flawed" and would not solve global pricing inequities. Richard Saynor told Reuters that the proposal - outlined in a letter to the Financial Times last week - ignores structural drivers of high drug prices in the United States. "It made me smile, made me laugh," Saynor said of the proposal, adding that he thinks the Trump administration will succeed in driving down prices for brand-name medicines. But he said big pharmaceutical companies should not respond by hiking prices in Europe, which would hurt patient access. Saynor argued that U.S. patients have long borne a disproportionate share of costs for innovative medicines, while large drugmakers maintain high margins. He cited Amgen's autoimmune treatment Enbrel, which costs $70,000 per patient per year in the U.S., compared with $7,000 in Europe. Earlier this month, Sandoz filed a U.S. antitrust lawsuit against Amgen, alleging the company blocked biosimilar competition, including Sandoz's own version. Biosimilars are near-identical copies of complex biologic drugs whose patents have expired. Saynor said some form of U.S. price reform is inevitable, pointing to President Donald Trump's stalled plan to link drug prices to international benchmarks during his first term. Reuters reported last week that the Trump administration is again weighing such a move. Saynor said the structure of the U.S. healthcare system - including pharmacy benefit managers - inflates prices and he likened PBMs to "leeches sucking value out of healthcare". Generic drugs account for more than 90% of prescriptions filled in the U.S. but just 17% of spending, according to the Association for Accessible Medicines, the main generic medicines trade body. Saynor said greater use of generic and biosimilar drugs could help fund access to genuine innovation, rather than sustaining high prices for older, patent-protected medicines. Swiss-headquartered Sandoz, which spun off from Novartis in 2023, is one of the world's largest makers of generic and biosimilar drugs. The company sells anti-infectives and generic narcotics for hospital use in the United States. Saynor said Sandoz's North America President Keren Haruvi, who also chairs the AAM, has been meeting with White House officials nearly every week to discuss pharmaceutical imports and U.S. reliance on foreign drug production. "They have some really tough choices to make about security of supply ... and I'm quite optimistic these are the right conversations to have ... about accessibility, affordability," he said. He warned that if significant tariffs are imposed, Sandoz could be forced to withdraw some products from the U.S. market.
